{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:53:26Z","timestamp":1790924006603,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2026-25475042"],"award-info":[{"award-number":["RS-2026-25475042"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"DOI":"10.1007\/s13346-026-02220-8","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:25:00Z","timestamp":1790875500000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Polymeric micelle delivery of a HER2-selective tyrosine kinase inhibitor for targeted breast cancer therapy"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3947-7052","authenticated-orcid":false,"given":"Jain","family":"Koo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1496-1270","authenticated-orcid":false,"given":"Hyewon","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7065-7604","authenticated-orcid":false,"given":"Jaehyun","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heeju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2396-5780","authenticated-orcid":false,"given":"Kyung Hoon","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4379-7238","authenticated-orcid":false,"given":"Kyung Taek","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2220_CR1","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(24)00747-5","volume":"403","author":"CE Coles","year":"2024","unstructured":"Coles CE, Earl H, Anderson BO, Barrios CH, Bienz M, Bliss JM, Cameron DA, Cardoso F, Cui W, Francis PA. The lancet breast cancer commission. Lancet. 2024;403:1895\u2013950. https:\/\/doi.org\/10.1016\/S0140-6736(24)00747-5.","journal-title":"Lancet"},{"key":"2220_CR2","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1016\/j.drudis.2022.06.007","volume":"27","author":"P Pandey","year":"2022","unstructured":"Pandey P, Arya DK, Ramar MK, Chidambaram K, Rajinikanth P. Engineered nanomaterials as an effective tool for HER2\u2009+\u2009breast cancer therapy. Drug Discov Today. 2022;27:2526\u201340. https:\/\/doi.org\/10.1016\/j.drudis.2022.06.007.","journal-title":"Drug Discov Today"},{"key":"2220_CR3","doi-asserted-by":"publisher","first-page":"112375","DOI":"10.1016\/j.biopha.2021.112375","volume":"145","author":"JA Malik","year":"2022","unstructured":"Malik JA, Ahmed S, Jan B, Bender O, Al Hagbani T, Alqarni A, Anwar S. Drugs repurposed: An advanced step towards the treatment of breast cancer and associated challenges. Biomed Pharmacother. 2022;145:112375. https:\/\/doi.org\/10.1016\/j.biopha.2021.112375.","journal-title":"Biomed Pharmacother"},{"key":"2220_CR4","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/annonc\/12.suppl_1.S3","volume":"12","author":"I Rubin","year":"2001","unstructured":"Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12:S3\u20138. https:\/\/doi.org\/10.1093\/annonc\/12.suppl_1.S3.","journal-title":"Ann Oncol"},{"key":"2220_CR5","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3390\/ph16101450","volume":"16","author":"X Xia","year":"2023","unstructured":"Xia X, Gong C, Zhang Y, Xiong H. The history and development of HER2 inhibitors. Pharmaceuticals. 2023;16:1450. https:\/\/doi.org\/10.3390\/ph16101450.","journal-title":"Pharmaceuticals"},{"key":"2220_CR6","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.drudis.2020.12.014","volume":"26","author":"RK Dhritlahre","year":"2021","unstructured":"Dhritlahre RK, Saneja A. Recent advances in HER2-targeted delivery for cancer therapy. Drug Discov Today. 2021;26:1319\u201329. https:\/\/doi.org\/10.1016\/j.drudis.2020.12.014.","journal-title":"Drug Discov Today"},{"key":"2220_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: Advances and future directions. Nat Rev Drug Discov. 2023;22:101\u201326. https:\/\/doi.org\/10.1038\/s41573-022-00579-0.","journal-title":"Nat Rev Drug Discov"},{"key":"2220_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejps.2017.01.021","volume":"110","author":"X Li","year":"2017","unstructured":"Li X, Yang C, Wan H, Zhang G, Feng J, Zhang L, Chen X, Zhong D, Lou L, Tao W. Discovery and development of pyrotinib: A novel irreversible EGFR\/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017;110:51\u201361. https:\/\/doi.org\/10.1016\/j.ejps.2017.01.021.","journal-title":"Eur J Pharm Sci"},{"key":"2220_CR9","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1039\/D5MD00025D","volume":"16","author":"JW Lee","year":"2025","unstructured":"Lee JW, Im CG, Lee JM, Cho M, Kim M, Lee K, Nguyen HTT, Seo J, Seo JH, Min KH. Discovery of isoquinoline-tethered quinazoline derivatives with enhanced HER2 inhibition over EGFR. RSC Med Chem. 2025;16:2174\u201389. https:\/\/doi.org\/10.1039\/D5MD00025D.","journal-title":"RSC Med Chem"},{"key":"2220_CR10","doi-asserted-by":"publisher","unstructured":"Alavi SE, Alavi SF, Koohi M, Raza A, Ebrahimi H, Shahmabadi. Nanoparticle-integrated metal\u2013organic frameworks: A revolution in next-generation drug delivery systems. J Pharm Investig. 2024;1\u201333. https:\/\/doi.org\/10.1007\/s40005-024-00691-w.","DOI":"10.1007\/s40005-024-00691-w"},{"key":"2220_CR11","doi-asserted-by":"publisher","first-page":"101662","DOI":"10.1016\/j.jddst.2020.101662","volume":"57","author":"X Fang","year":"2020","unstructured":"Fang X, Cao J, Shen A. Advances in anti-breast cancer drugs and the application of nano-drug delivery systems in breast cancer therapy. J Drug Deliv Sci Technol. 2020;57:101662. https:\/\/doi.org\/10.1016\/j.jddst.2020.101662.","journal-title":"J Drug Deliv Sci Technol"},{"key":"2220_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40005-019-00459-7","volume":"50","author":"P Tran","year":"2020","unstructured":"Tran P, Lee S-E, Kim D-H, Pyo Y-C, Park J-S. Recent advances of nanotechnology for the delivery of anticancer drugs for breast cancer treatment. J Pharm Investig. 2020;50:261\u201370. https:\/\/doi.org\/10.1007\/s40005-019-00459-7.","journal-title":"J Pharm Investig"},{"key":"2220_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4155\/tde.15.90","volume":"7","author":"A Mittal","year":"2016","unstructured":"Mittal A, Chitkara D. Structural modifications in polymeric micelles to impart multifunctionality for improved drug delivery. Ther Deliv. 2016;7:73\u201387. https:\/\/doi.org\/10.4155\/tde.15.90.","journal-title":"Ther Deliv"},{"key":"2220_CR14","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1002\/cam4.5302","volume":"12","author":"S Yamashita","year":"2023","unstructured":"Yamashita S, Kojima M, Onda N, Yoshida T, Shibutani M. Trastuzumab-based near\u2010infrared photoimmunotherapy in xenograft mouse of breast cancer. Cancer Med. 2023;12:4579\u201389. https:\/\/doi.org\/10.1002\/cam4.5302.","journal-title":"Cancer Med"},{"key":"2220_CR15","doi-asserted-by":"publisher","first-page":"21753","DOI":"10.1038\/s41598-023-49010-7","volume":"13","author":"J Li","year":"2023","unstructured":"Li J, Yao J, Qi L. HER2 low expression breast cancer subtyping and their correlation with prognosis and immune landscape based on the histone modification related genes. Sci Rep. 2023;13:21753. https:\/\/doi.org\/10.1038\/s41598-023-49010-7.","journal-title":"Sci Rep"},{"key":"2220_CR16","doi-asserted-by":"publisher","first-page":"10194","DOI":"10.3390\/ijms231710194","volume":"23","author":"D de Abreu Pereira","year":"2022","unstructured":"de Abreu Pereira D, Sandim V, Fernandes TF, Almeida VH, Rocha MR, do Amaral RJ, Rossi MID, Kalume DE, Zingali RB. Proteomic analysis of HCC-1954 and MCF-7 cell lines highlights crosstalk between \u03b1v and \u03b21 integrins, E-cadherin and HER-2. Int J Mol Sci. 2022;23:10194. https:\/\/doi.org\/10.3390\/ijms231710194.","journal-title":"Int J Mol Sci"},{"key":"2220_CR17","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00289-016-1791-3","volume":"74","author":"NH Hoang","year":"2017","unstructured":"Hoang NH, Lim C, Sim T, Lee ES, Youn YS, Kim D, Oh KT. Characterization of a triblock copolymer, poly(ethylene glycol)-polylactide-poly(ethylene glycol), with different structures for anticancer drug delivery applications. Polym Bull. 2017;74:1595\u2013609. https:\/\/doi.org\/10.1007\/s00289-016-1791-3.","journal-title":"Polym Bull"},{"key":"2220_CR18","doi-asserted-by":"publisher","first-page":"101862","DOI":"10.1016\/j.nantod.2023.101862","volume":"50","author":"Y Shin","year":"2023","unstructured":"Shin Y, Kim M, Lee ES, Lim C, Oh KT. RNA-seq-guided triple-combination nano-system of gold nanocluster, quercetin, and docetaxel for ultimate synergistic photothermal-chemotherapy against MDR tumor. Nano Today. 2023;50:101862. https:\/\/doi.org\/10.1016\/j.nantod.2023.101862.","journal-title":"Nano Today"},{"key":"2220_CR19","doi-asserted-by":"publisher","first-page":"e0170186","DOI":"10.1371\/journal.pone.0170186","volume":"12","author":"V Mpakou","year":"2017","unstructured":"Mpakou V, Papadavid E, Kontsioti F, Konsta E, Vikentiou M, Spathis A, Papageorgiou S, Vasilatou D, Gkontopoulos K, Mpazani E. Apoptosis induction and gene expression profile alterations of cutaneous T-cell lymphoma cells following their exposure to bortezomib and methotrexate. PLoS ONE. 2017;12:e0170186. https:\/\/doi.org\/10.1371\/journal.pone.0170186.","journal-title":"PLoS ONE"},{"key":"2220_CR20","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s10895-018-2306-4","volume":"28","author":"E Ko\u00e7","year":"2018","unstructured":"Ko\u00e7 E, \u00c7elik-Uzuner S, Uzuner U, \u00c7akmak R. The detailed comparison of cell death detected by annexin V-PI counterstain using fluorescence microscope, flow cytometry and automated cell counter in mammalian and microalgae cells. J Fluoresc. 2018;28:1393\u2013404. https:\/\/doi.org\/10.1007\/s10895-018-2306-4.","journal-title":"J Fluoresc"},{"key":"2220_CR21","doi-asserted-by":"publisher","first-page":"1934578X2514093","DOI":"10.1177\/1934578X251409306","volume":"20","author":"X Shi","year":"2025","unstructured":"Shi X, Wang M, Xu D, Chen J, Wang J. Mechanistic exploration and experimental validation of Yadanzi oil in treating breast cancer based on network pharmacology and molecular docking technology. Nat Prod Commun. 2025;20:1934578X251409306. https:\/\/doi.org\/10.1177\/1934578X251409306.","journal-title":"Nat Prod Commun"},{"key":"2220_CR22","doi-asserted-by":"publisher","unstructured":"Quazi S, Huynh N, Rigopoulos A, Mcdonald A, Ackermann U, Scott AM, Burvenich IJG. Using 16\u03b1-[18F]-fluoro-17\u03b2-estradiol PET to visualize estrogen receptor \u03b1 expression in human breast cancer xenografts in female ovariectomized mice. J Vis Exp. 2025;e67151. https:\/\/doi.org\/10.3791\/67151.","DOI":"10.3791\/67151"},{"key":"2220_CR23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.carbpol.2017.10.052","volume":"181","author":"Z Wu","year":"2018","unstructured":"Wu Z, Wu J, Zhang R, Yuan S, Lu Q, Yu Y. Colloid properties of hydrophobic modified alginate: Surface tension, \u03b6-potential, viscosity and emulsification. Carbohydr Polym. 2018;181:56\u201362. https:\/\/doi.org\/10.1016\/j.carbpol.2017.10.052.","journal-title":"Carbohydr Polym"},{"key":"2220_CR24","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jconrel.2024.12.058","volume":"378","author":"J Koo","year":"2025","unstructured":"Koo J, Shin Y, Jeon H, Cheong J, Cho S, Park C, Song EC, Ramsey JD, Lim C, Oh KT. Enhancing glioblastoma therapy via intranasal administration of highly potent cell-penetrating peptide decorated nanoparticles. J Control Release. 2025;378:997\u20131012. https:\/\/doi.org\/10.1016\/j.jconrel.2024.12.058.","journal-title":"J Control Release"},{"key":"2220_CR25","doi-asserted-by":"publisher","unstructured":"Jeon H, Joo Y, Husni P, Poon C-D, Lee ES, Youn YS, Shin Y, Lim C, Oh KT. Architecture-driven optimization of nanocarriers for pH-responsive drug delivery. J Pharm Investig. 2026;1\u201318. https:\/\/doi.org\/10.1007\/s40005-025-00801-2.","DOI":"10.1007\/s40005-025-00801-2"},{"key":"2220_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12943-025-02410-x","volume":"24","author":"P Kesharwani","year":"2025","unstructured":"Kesharwani P, Kumar V, Goh KW, Gupta G, Alsayari A, Wahab S, Sahebkar A. PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy. Mol Cancer. 2025;24:205. https:\/\/doi.org\/10.1186\/s12943-025-02410-x.","journal-title":"Mol Cancer"},{"key":"2220_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","volume":"7","author":"I Schlam","year":"2021","unstructured":"Schlam I, Swain SM. HER2-positive breast cancer and tyrosine kinase inhibitors: The time is now. NPJ Breast Cancer. 2021;7:56. https:\/\/doi.org\/10.1038\/s41523-021-00265-1.","journal-title":"NPJ Breast Cancer"},{"key":"2220_CR28","doi-asserted-by":"publisher","unstructured":"Zhang Y, Wu S, Zhuang X, Weng G, Fan J, Yang X, Xu Y, Pan L, Hou T, Zhou Z. Identification of an activating mutation in the extracellular domain of HER2 conferring resistance to pertuzumab. Onco Targets Ther. 2019;11597\u2013608. https:\/\/doi.org\/10.2147\/OTT.S232912.","DOI":"10.2147\/OTT.S232912"},{"key":"2220_CR29","doi-asserted-by":"publisher","first-page":"1089066","DOI":"10.3389\/fphar.2022.1089066","volume":"13","author":"DD Singh","year":"2022","unstructured":"Singh DD, Lee H-J, Yadav DK. Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer. Front Pharmacol. 2022;13:1089066. https:\/\/doi.org\/10.3389\/fphar.2022.1089066.","journal-title":"Front Pharmacol"},{"key":"2220_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12272-022-01376-4","volume":"45","author":"JW Lee","year":"2022","unstructured":"Lee JW, Choi C, Kim J, Lee S, Kim J, Lee Y, Min KH. Structure\u2013activity relationships of novel quinazoline derivatives with high selectivity for HER2 over EGFR. Arch Pharm Res. 2022;45:123\u201341. https:\/\/doi.org\/10.1007\/s12272-022-01376-4.","journal-title":"Arch Pharm Res"},{"key":"2220_CR31","doi-asserted-by":"publisher","unstructured":"Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update. Pharmacol Res. 2024;107059. https:\/\/doi.org\/10.1016\/j.phrs.2024.107059.","DOI":"10.1016\/j.phrs.2024.107059"},{"key":"2220_CR32","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ctrv.2015.08.001","volume":"41","author":"V D\u2019Amato","year":"2015","unstructured":"D\u2019Amato V, Raimondo L, Formisano L, Giuliano M, De Placido S, Rosa R, Bianco R. Mechanisms of lapatinib resistance in HER2-driven breast cancer. Cancer Treat Rev. 2015;41:877\u201383. https:\/\/doi.org\/10.1016\/j.ctrv.2015.08.001.","journal-title":"Cancer Treat Rev"},{"key":"2220_CR33","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.clbc.2016.05.016","volume":"16","author":"SR Tiwari","year":"2016","unstructured":"Tiwari SR, Mishra P, Abraham J. Neratinib, a novel HER2-targeted tyrosine kinase inhibitor. Clin Breast Cancer. 2016;16:344\u20138. https:\/\/doi.org\/10.1016\/j.clbc.2016.05.016.","journal-title":"Clin Breast Cancer"},{"key":"2220_CR34","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1200\/JCO.2016.69.6179","volume":"35","author":"F Ma","year":"2017","unstructured":"Ma F, Li Q, Chen S, Zhu W, Fan Y, Wang J, Luo Y, Xing P, Lan B, Li M. Phase I study and biomarker analysis of pyrotinib, a novel irreversible Pan-ERBB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2\u2013positive metastatic breast cancer. J Clin Oncol. 2017;35:3105\u201312. https:\/\/doi.org\/10.1200\/JCO.2016.69.6179.","journal-title":"J Clin Oncol"},{"key":"2220_CR35","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ijpharm.2016.10.058","volume":"515","author":"A-H Ranneh","year":"2016","unstructured":"Ranneh A-H, Iwao Y, Noguchi S, Oka T, Itai S. The use of surfactants to enhance the solubility and stability of the water-insoluble anticancer drug SN38 into liquid crystalline phase nanoparticles. Int J Pharm. 2016;515:501\u20135. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.10.058.","journal-title":"Int J Pharm"},{"key":"2220_CR36","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.msec.2018.10.015","volume":"94","author":"Z Izadiyan","year":"2019","unstructured":"Izadiyan Z, Basri M, Masoumi HRF, Karjiban RA, Salim N, Kalantari K. Improvement of physicochemical properties of nanocolloidal carrier loaded with low water solubility drug for parenteral cancer treatment by response surface methodology. Mater Sci Eng C. 2019;94:841\u20139. https:\/\/doi.org\/10.1016\/j.msec.2018.10.015.","journal-title":"Mater Sci Eng C"},{"key":"2220_CR37","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3390\/pharmaceutics12060510","volume":"12","author":"MA Shetab Boushehri","year":"2020","unstructured":"Shetab Boushehri MA, Dietrich D, Lamprecht A. Nanotechnology as a platform for the development of injectable parenteral formulations: A comprehensive review of the know-hows and state of the art. Pharmaceutics. 2020;12:510. https:\/\/doi.org\/10.3390\/pharmaceutics12060510.","journal-title":"Pharmaceutics"},{"key":"2220_CR38","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1517\/17425241003596337","volume":"7","author":"C-X He","year":"2010","unstructured":"He C-X, He Z-G, Gao J-Q. Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs. Expert Opin Drug Deliv. 2010;7:445\u201360. https:\/\/doi.org\/10.1517\/17425241003596337.","journal-title":"Expert Opin Drug Deliv"},{"key":"2220_CR39","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1021\/acs.molpharmaceut.4c01325","volume":"22","author":"L Weng","year":"2025","unstructured":"Weng L, Zhao M, Chen Z, Zhu L. Hypoxia-targeted responsive delivery of doxorubicin and digoxin for synergistic treatment of triple-negative breast cancer. Mol Pharm. 2025;22:2142\u201358. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c01325.","journal-title":"Mol Pharm"},{"key":"2220_CR40","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.apsb.2021.02.018","volume":"11","author":"X Meng","year":"2021","unstructured":"Meng X, Zhang Z, Tong J, Sun H, Fawcett JP, Gu J. The biological fate of the polymer nanocarrier material monomethoxy poly (ethylene glycol)-block-poly (d, l-lactic acid) in rat. Acta Pharm Sin B. 2021;11:1003\u20139. https:\/\/doi.org\/10.1016\/j.apsb.2021.02.018.","journal-title":"Acta Pharm Sin B"},{"key":"2220_CR41","doi-asserted-by":"publisher","first-page":"e35318","DOI":"10.1002\/jbm.b.35318","volume":"112","author":"M Jurczyk","year":"2024","unstructured":"Jurczyk M, Musia\u0142-Kulik M, Fory\u015b A, Godzierz M, Kaczmarczyk B, Kasperczyk J, Wrze\u015bniok D, Beberok A, Jelonek K. Comparison of PLLA\u2010PEG and PDLLA\u2010PEG micelles for co\u2010encapsulation of docetaxel and resveratrol. J Biomed Mater Res B Appl Biomater. 2024;112:e35318. https:\/\/doi.org\/10.1002\/jbm.b.35318.","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"2220_CR42","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1021\/bm300325v","volume":"13","author":"DG Abebe","year":"2012","unstructured":"Abebe DG, Fujiwara T. Controlled thermoresponsive hydrogels by stereocomplexed PLA-PEG-PLA prepared via hybrid micelles of pre-mixed copolymers with different PEG lengths. Biomacromolecules. 2012;13:1828\u201336. https:\/\/doi.org\/10.1021\/bm300325v.","journal-title":"Biomacromolecules"},{"key":"2220_CR43","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1021\/acs.molpharmaceut.6b01169","volume":"14","author":"H Soleymani Abyaneh","year":"2017","unstructured":"Soleymani Abyaneh H, Vakili MR, Shafaati A, Lavasanifar A. Block copolymer stereoregularity and its impact on polymeric micellar nanodrug delivery. Mol Pharm. 2017;14:2487\u2013502. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b01169.","journal-title":"Mol Pharm"},{"key":"2220_CR44","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1007\/s12274-018-2152-3","volume":"11","author":"Y Lu","year":"2018","unstructured":"Lu Y, Zhang E, Yang J, Cao Z. Strategies to improve micelle stability for drug delivery. Nano Res. 2018;11:4985\u201398. https:\/\/doi.org\/10.1007\/s12274-018-2152-3.","journal-title":"Nano Res"},{"key":"2220_CR45","doi-asserted-by":"publisher","first-page":"10555","DOI":"10.1038\/s41467-025-65590-6","volume":"16","author":"M-m Zhan","year":"2025","unstructured":"Zhan M-m, Chen H, He M, Song C, Jiao Z, Liu N, Liu Z, Hou Z, Chen Y, Song Z. Highly efficient and long-acting split-and-mix proteolysis targeting chimera based on self-assembled polylactic acid. Nat Commun. 2025;16:10555. https:\/\/doi.org\/10.1038\/s41467-025-65590-6.","journal-title":"Nat Commun"},{"key":"2220_CR46","doi-asserted-by":"publisher","unstructured":"Hu Y, Ran M, Wang B, Lin Y, Cheng Y, Zheng S. Co-delivery of docetaxel and curcumin via nanomicelles for enhancing anti-ovarian cancer treatment. Int J Nanomed. 2020;9703\u201315. https:\/\/doi.org\/10.2147\/IJN.S274083.","DOI":"10.2147\/IJN.S274083"},{"key":"2220_CR47","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1016\/j.biomaterials.2013.12.096","volume":"35","author":"Y Yu","year":"2014","unstructured":"Yu Y, Zhang X, Qiu L. The anti-tumor efficacy of curcumin when delivered by size\/charge-changing multistage polymeric micelles based on amphiphilic poly (\u03b2-amino ester) derivates. Biomaterials. 2014;35:3467\u201379. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.12.096.","journal-title":"Biomaterials"},{"key":"2220_CR48","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1016\/j.cclet.2021.11.076","volume":"33","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Li T, Hu Y, Chen J, He Y, Gao X, Zhang Y. Co-delivery of doxorubicin and curcumin via cRGD-peptide modified PEG-PLA self-assembly nanomicelles for lung cancer therapy. Chin Chem Lett. 2022;33:2507\u201311. https:\/\/doi.org\/10.1016\/j.cclet.2021.11.076.","journal-title":"Chin Chem Lett"},{"key":"2220_CR49","doi-asserted-by":"publisher","first-page":"5778","DOI":"10.1039\/c3tb21091j","volume":"1","author":"X Gao","year":"2013","unstructured":"Gao X, Zheng F, Guo G, Liu X, Fan R, Qian Z-y, Huang N, Wei Y-q. Improving the anti-colon cancer activity of curcumin with biodegradable nano-micelles. J Mat Chem B. 2013;1:5778\u201390. https:\/\/doi.org\/10.1039\/c3tb21091j.","journal-title":"J Mat Chem B"},{"key":"2220_CR50","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1158\/1535-7163.MCT-11-0987","volume":"11","author":"JR Hasenstein","year":"2012","unstructured":"Hasenstein JR, Shin H-C, Kasmerchak K, Buehler D, Kwon GS, Kozak KR. Antitumor activity of Triolimus: A novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG. Mol Cancer Ther. 2012;11:2233\u201342. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0987.","journal-title":"Mol Cancer Ther"},{"key":"2220_CR51","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S1875-5364(25)60919-8","volume":"23","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Su S, Xu X, He Z, Zhou Y, Lu X, Jiang A. Caerulomycin A disrupts glucose metabolism and triggers ER stress-induced apoptosis in triple-negative breast cancer cells. Chin J Nat Med. 2025;23:1080\u201391. https:\/\/doi.org\/10.1016\/S1875-5364(25)60919-8.","journal-title":"Chin J Nat Med"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02220-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02220-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02220-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:01:36Z","timestamp":1790920896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02220-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":51,"alternative-id":["2220"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02220-8","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article contains no studies with human subjects performed by any authors. Instead, all animal care and in vivo experiments adhered to the approved protocol of the Institutional Animal Care and Use Committee of Chung-Ang University (license number: A2021019), following National Institute of Health guidelines \u201cGuide for the Care and Use of Laboratory Animals\u201d and \u201cAnimal Protection Law in the Republic of Korea\u201d.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}